Introduction
Materials and methods
Patient population
Echocardiographic examination
Assessment of LV deformation function
DPD scintigraphy
Statistics
Ethics
Results
ATTR- CA (n = 51) | HFnCA (n = 20) | P-value | |
---|---|---|---|
NT-proBNP log, ng/L | 3.1 ± 0.6 | 2.8 ± 0.6 | 0.045 |
Troponin, ng/L | 31.5 (35) | 23 (19) | 0.086 |
SBP, mmHg | 130 ± 20 | 140 ± 17 | 0.061 |
DBP, mmHg | 78 ± 10 | 84 ± 10 | 0.046 |
Height,cm | 175 ± 8 | 175 ± 9 | 0.799 |
Weight, kg | 78 ± 13 | 92 ± 21 | < 0.001 |
Female sex (%) | 30 (59%) | 5 (29%) | 0.017 |
Follow up time, years | 6 ± 2 | 8 ± 2 | < 0.001 |
NYHA, 2,3A,3B (%) | – | 14/63/21 | |
Betablockers, n | 20 | 19 | |
ACE/ARB, n | 15 | 20 | |
MRA/Furosemid, n | 12/12 | 6 | |
HFpEF, n | 38 | 13 | |
HFmrEF, n | 13 | 6 | |
HFrEF, n | 3 | 1 |
Disease progression in ATTR-CA and HFnCA
ATTR-CA (n = 51) | HFnCA (n = 20) | |||
---|---|---|---|---|
First echo | Last echo | First echo | Last echo | |
Age, years | 72 ± 7 | 78 ± 7* | 68 ± 7 | 76 ± 7** |
HR, bpm | 74 (61) | 70 (60) | 66 (14) | 69 (21) |
IVS,mm | 16 (4) | 18 (5)*** | 16 (3) | 16 (4) |
LVDD, mm | 45 ± 5 | 44 ± 5 | 51 ± 9 | 48 ± 7 |
PWT, mm | 12 (3) | 14 (3)*** | 10 (2) | 11 (5) |
LAV, ml | 74 (54) | 90 (115)* | 60 (45) | 114 (124) |
RWT, mm | 0.51 (0.17) | 0.62 (0.21)*** | 0.45 (0.17) | 0.3 8(0.44) |
GLS, % | – 18.0 ± 4.8 | – 13.2 ± 4.8* | – 13.1 ± 6.0 | – 11.1 ± 2.8 |
RV-RA, mmHg | 26 (8) | 25 (15) | 24 (3) | 27 (31) |
E velocity,cm/s | 73 ± 25 | 62 ± 24 | 70 ± 20 | 62 ± 23 |
RELAPS | 2.2 ± 0.6 | 2.0 ± 0.9 | 1.6 ± 0.5 | 1.4 ± 1.6 |
AF, % | 8 | 27* | 1 | 2 |
ATTRwt versus ATTRv
ATTRwt (n = 16) | ATTRv (n = 35) | |||
---|---|---|---|---|
First echo | Last echo | First echo | Last echo | |
Age, years | 80 ± 5 | 84 ± 6* | 69 ± 6 | 75 ± 6*** |
HR, bpm | 77 ± 19 | 72 ± 12 | 76 ± 12 | 66 ± 13 |
IVS, mm | 15 (5) | 16 (3)* | 16 (5) | 20 (7)*** |
LVDD, mm | 46 ± 6 | 45 ± 5* | 45 ± 5 | 43 ± 5 |
PWT, mm | 11.5 ± 1.6 | 13.0 ± 1.9* | 11.9 ± 2.7 | 14.4 ± 3.2* |
LAV, ml | 80 (49) | 82 (35) | 50 (30) | 79 (40)*** |
RWT, mm | 0.54 (0.19) | 0.57 (0.17) * | 0.51 (0.20) | 0.65 (0.20) *** |
GLS, % | 15 ± 5 | 12 ± 3.0 | 19 ± 4 | 14 ± 3 |
RELAPS | 2.2 (0.8) | 1.3 (0.7)*** | 2.3 (0.4) | 2.2 (1.0) |
AF, (%) | 5 | 11* | 2 | 15*** |
Female sex (n) | 2 | 28 |
Disease progression rate in ATTR-CA and HFnCA
Disease progression rate in ATTRwt and ATTRv
ATTR-CA (n = 51) | HFnCA (n = 20) | P-value | |
ΔIVS/year | 0.39 (0.92) | 0.25 (0.37) | 0.009 |
ΔRWT/year | 0.023 ± 0.035 | 0.003 ± 0.017 | 0.022 |
ΔRELAPS/year | 0.065 (0.17) | 0.030 (0.27) | 1.000 |
ΔGLS/year | 0.50 (1.3) | 0.76 (1.2) | 0.055 |
ATTRwt (n = 16) | ATTRv (n = 35) | P-value | |
ΔIVS/year | 0.57 ± 0.54 | 0.54 ± 0.51 | 0.844 |
ΔRWT/year | 0.008 ± 0.02 | 0.029 ± 0.04 | 0.012 |
ΔRELAPS/year | 0.06 ± 0.21 | 0.06 ± 0.18 | 0.878 |
ΔGLS/year | 0.34 ± 1.4 | 0.88 ± 0.90 | 0.127 |
ATTR-CA HT (n = 15) | ATTR-CA nHT (n = 34) | ||
ΔIVS/year | 0.66 ± 0.62 | 0.52 ± 0.47 | 0.406 |
ΔRWT/year | 0.021 ± 0.031 | 0.024 ± 0.038 | 0.831 |
ΔRELAPS/year | 0.079 ± 0.20 | 0.061 ± 0.23 | 0.803 |
ΔGLS/year | 0.60 ± 1.60 | 0.57 ± 0.78 | 0.363 |